Key facts
- This page summarizes FIL Ltd's Form 4 filing for Xilio Therapeutics, Inc. (XLO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 28 Oct 2021, 15:57.
FIL Ltd - 26 Oct 2021 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)
- SEC form
- 4
- Accepted by SEC
- 28 Oct 2021, 15:57:55 UTC
- Prior SEC filing
- 21 Oct 2021
- Next SEC filing
- 02 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- Kevin M. Meagher, Duly authorized under Powers of Attorney, by and on behalf of Eight Roads Shareholdings Limited and its direct and indirect subsidiaries, Eight Roads Holdings Limited and Eight Roads Investments
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
FIL Ltd filed Form 4 for Xilio Therapeutics, Inc. (XLO) on 28 Oct 2021.
Change
- Previous filing in this sequence was filed on 21 Oct 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
XLO
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +218,705
- Change %
- Price
- Shares after
- 218,705
- Date
- 26 Oct 2021
- Ownership
- Eight Roads Investments
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
XLO
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -2,077,698
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 26 Oct 2021
- Ownership
- Eight Roads Investments
- Underlying class
- Common Stock
- Underlying amount
- 218,705
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
FIL Ltd is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.
SEC remarks
Remark 1: Each of Eight Roads Shareholdings Limited ("ERSL") and Pandanus Partners, L.P. ("Pandanus") owns shares of Eight Roads Holdings Limited ("ERHL") voting stock. ERHL is the immediate parent company of Eight Roads Investments ("ERI"), which owns the shares being reported on with this Form. While the percentage of total voting power represented by ERSL's and Pandanus' shares of ERHL voting stock may fluctuate as a result of changes in the total number of shares of ERHL voting stock outstanding from time to time, ERSL's holding normally represents more than 50% and Pandanus' holding normally represents more than 25% and less than 50% of, in each case, the total votes which may be cast by all holders of ERHL voting stock. The shares in ERSL are owned primarily by officers and senior employees of FIL Limited and Eight Roads together with several charitable organizations. No such person or organization owns or controls more than 25% of the voting stock in ERSL. Pandanus Associates, Inc. ("PAI") acts as general partner of Pandanus. Pandanus is owned by trusts for the benefit of members of the Johnson family, including ERHL's Chairman Abigail P. Johnson, but disclaims that any such member is a beneficial owner of the securities reported on this form. The address of ERSL, ERHL and ERI is 42 Crow Lane, Hamilton HM19, Bermuda. The address of Pandanus is c/o FIL Limited, 42 Crow Lane, Hamilton HM19, Bermuda. The address of PAI is 11 Keewaydin Drive, Suite 100, Salem, NH, USA, 03079. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein.